Evommune stock: Analyst Estimates
EVMNFor Evommune, analysts expect revenue of $3.13M (down 76%) and adjusted earnings per share of −$3.48 on average for fiscal year 2026.
This is what analysts expect for Evommune, Inc. on average. These are estimates, not promises and not a recommendation by MEQIRI. We deliberately do not show price targets.
Reported and expected
The last fiscal years from the annual reports, then the average analyst estimates.
| Fiscal year | Type | Revenue | Growth | Net income | EPS | Analysts |
|---|---|---|---|---|---|---|
| 2023 | Reported | $5M | no data | −$34.05M | −$1.13 | |
| 2024 | Reported | $7M | 40.0% | −$66.81M | −$2.27 | |
| 2025 | Reported | $13M | 85.7% | −$68.87M | −$11.22 | |
| 2026 | Estimate | $3.13M | −76.0% | −$20.97M | −$3.48 | 9 |
| 2027 | Estimate | $222.22K | −92.9% | −$20M | −$3.51 | 9 |
Earnings per share in the estimates are usually adjusted, the way analysts calculate them. The reported figure is the statutory one and can therefore differ.
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
